# \[e-med\] Fondation DNDi: 1er appel � propositions **URL:** https://talk.edrugplus.org/t/e-med-fondation-dndi-1er-appel-propositions/18787 **Category:** e-med **Created:** [February 4, 2004, 2:30pm UTC](https://talk.edrugplus.org/t/e-med-fondation-dndi-1er-appel-propositions/18787 "2004-02-04T14:30:46Z") **Posts on this page:** 1 **Page:** 1
### Author: ![remed9](https://avatars.discourse-cdn.com/v4/letter/r/22d042/32.png) [@remed9](https://talk.edrugplus.org/u/remed9) #### Post date: [February 4, 2004, 2:30pm UTC](https://talk.edrugplus.org/t/e-med-fondation-dndi-1er-appel-propositions/18787/1 "2004-02-04T14:30:46Z")
E-MED: Fondation DNDi: 1er appel � propositions --------------------------------------------------------------------- [La fondation DNDi soutenue par Msf lance son premier appel � propositions pour financer des travaux de recherche sur de nouveaux m�dicaments pour soigner la trypanosomiase, la maladie de Chagas et les leischmanioses...as you can see in english only! date limite le 15 mars 2003.CB] DNDi Drugs for negleted Diseases initiative CALL FOR LETTERS OF INTEREST Human African Trypanosomiasis, Chagas Disease, Leishmaniasis Funding for collaborative projects from drug discovery to advanced development BACKGROUND The Drugs for Neglected Diseases Initiative (DNDi) is a not-for-profit entity established in partnership with M�decins Sans Fronti�res, Oswaldo Cruz Foundation/Far Manguinhos, the Indian Council of Medical Research, Institut Pasteur, the Ministry of Health of Malaysia, and the Kenya Medical Research Institute, with WHO/TDR as a permanent observer. Its goal is to develop effective, safe, affordable and field-adapted drugs by addressing the needs of patients suffering from the most neglected communicable diseases. The DNDi acts in the public interest to bridge the existing gaps in research and development for essential drugs for neglected diseases such as sleeping sickness, Chagas disease, and leishmaniasis. The DNDi wishes to identify research opportunities to address unmet medical needs and initiate and coordinate drug R&D projects in collaboration with the international research community, the public sector, the pharmaceutical industry, and other relevant partners. In addition, the DNDi will support the implementation of research projects, including those in collaboration with South-South and North-South R&D networks. The DNDi aims to build its R&D portfolio with drug discovery projects (targeted at the identification of novel drug development candidates) and drug development projects (taking candidate compounds through the different stages of development to the point where they can be registered and recommended for use). CALL FOR LETTERS OF INTEREST DNDi wishes to continue to expand its project portfolio. In addition to the ongoing proactive project identification, DNDi is inviting letters of interest for drug discovery and drug development projects focusing on human African trypanosomiasis, Chagas disease, and leishmaniasis. Drug Discovery Projects are those directed at the discovery and identification of lead compounds for development of new chemical entities to be entered into pre-development studies. Projects both at early and late stages in the discovery process qualify. Drug Development Projects are those at the transitioning, pre-development and development stages. In addition to the development of new chemical entities (which can be at any of the above-mentioned stages), the DNDi will also consider: � Reformulation of an existing drug to be better adapted to the conditions of use or to the target population � Extension of indication of an existing drug to include one of the target diseases � Extension of registration to other geographical areas � New regimens and combinations of existing drugs. This invitation is open to the entire scientific community and the DNDi will consider all research and activities likely to lead to new drugs for these neglected diseases. Applications from academic groups and biotechnology or pharmaceutical companies, as well as from collaborative efforts between academic institutions and pharmaceutical companies are welcome. Projects involving North-South and South-South collaborations and projects conducted in association with scientific groups from disease-endemic countries are highly encouraged. HOW TO SUBMIT YOUR PROPOSAL Letters of interest must be no more than three pages in length. If you have several approaches or project proposals that you would like to submit for consideration, please submit each as a separate application. As the letter must be relatively brief, please restrict your application to the following points: 1. Rationale for the project. 2. Project status � Stage of project, i.e., target identification, target validation, lead compound identification, lead compound optimization, transitioning, pre-development, development (pre-clinical, phase I, II, III). 3. A clear description of the research activities proposed � For lead compounds and development projects, provide chemical structures. � For drug discovery projects, outline of all steps involved in the identification and optimization of a candidate molecule and all issues that will need to be addressed. � For drug development projects, address the following issues: � Evidence of in vivo efficacy � Preferably, indication of safety � Whenever applicable, elements of chemical feasibility (ease of synthesis; yield; stability; cost-of-goods; supplies; scalability) and pharmaceutical feasibility (bioavailability; stability in tropical climates; scalability) � A summary of the entire development plan, with budget estimates for each phase � Indication of affordability, sustainability, suitability of the drug and its impact on disease control efforts and strategies. 4. Project leaders, resource requirements (consumables, personnel, etc.), and the specific areas where DNDi funding is required for the complete and thorough development of a drug discovery project. SELECTION PROCESS Following receipt of the letters of interest, projects will be judged by relevance, scientific merit, and likelihood of success. A pre-selection of projects will be made by DNDi�s Scientific Advisory Committee. Detailed written proposals will then be sought from the principal investigators of the chosen projects. Following a detailed review by the Scientific Advisory Committee, final decisions on selection and financial support will be made by the DNDi�s Board of Directors. The ultimate goal of obtaining effective, safe, affordable and field-adapted drugs addressing the needs of neglected patients will guide the project selection process. SUBMISSION PROCEDURE Letters of interest should be submitted electronically in a Word or Pdf document to the email address submissions@dndi.org no later than March 15, 2004. All information will be kept strictly confidential. For more information on DNDi, please visit www.dndi.org -- Adresse pour les messages destin�s au forum E-MED: e-med@healthnet.org Pour r�pondre � un message envoyer la r�ponse au forum ou directement � l'auteur. Pour vous inscrire, vous d�sinscrire et consulter les archives de e-med: [http://www.essentialdrugs.org/emed/](http://www.essentialdrugs.org/emed/) Pour toutes autres questions addresser vos messages �: e-med-help@healthnet.org